Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Document › Details

Miltenyi Biotec B.V. & Co. KG. (7/14/20). "Press Release: Miltenyi Biotec Offers Automated and Closed Adherent Cell Culture Solutions on CliniMACS Prodigy". Bergisch Gladbach.

Organisation Organisation Miltenyi Biotec B.V. & Co. KG
  Group Miltenyi Biotec (Group)
Products Product CliniMACS Prodigy® Adherent Cell Culture System
  Product 2 CliniMACS Prodigy® platform
Persons Person Bosio, Andreas (Miltenyi Biotec 202007 Senior RnD Manager)
  Person 2 Hafseth, James (Miltenyi Biotec 202001 Communications Manager)

End-to-end automatic cultivation of adherent stem cells and derivatives from a single instrument

Miltenyi Biotec announced the immediate availability of its new CliniMACS Prodigy® Adherent Cell Culture System. A flexible architecture specifically developed for the GMP-compliant CliniMACS Prodigy Platform, it enables the automated, scalable, and closed manufacturing of various adherent cell types, including stem cells and their derivatives. Tested processes include, for example, GMP-compliant expansion of human mesenchymal stromal cells, and pluripotent stem cells, as well as differentiation of the latter into dopaminergic progenitors.

The CliniMACS Prodigy Adherent Cell Culture System’s modular nature allows users to build customized and automated manufacturing processes suitable for the culture of adherent cell types in a closed system and a single instrument. This minimizes operator influences and open handling steps, thus increasing product consistency. Meanwhile, it  reduces the requirements for high-class cleanroom facilities and manual operations, which represents significant cost savings on cleanroom operations and labor hours. Taken together, the CliniMACS Prodigy Adherent Cell Culture System is capable of meeting the various demands of regenerative medicine, in particular for reliable and cost-effective cell manufacturing to ultimately support cell therapies.

Regenerative medicine has become a key focus of labs and clinics worldwide, and the number of clinical trials using stem cells – especially pluripotent stem cells – is increasing rapidly every year.

Dr. Andreas Bosio, Senior R&D Manager at Miltenyi Biotec commented: “We have learned a lot from cell therapies using hematopoietic stem cells, and more recently CAR-T cells, and are now ready to transfer this knowledge to pluripotent stem cell–based therapies. This system enables routine production of small phase I batches up to mass production of thousands of doses in a ballroom approach. Moreover, the system is flexible enough to be used for experimental optimization of early-stage manufacturing protocols, for example, for new cell types.”

Prof. Dr. Annelise Bennaceur-Griscelli, University Paris Saclay, APHP– CITHERA Inserm UMR 935, found the CliniMACS Prodigy provided a safe and standardized, scalable manufacturing platform for GMP-iPSC master cell banks when using it to provide automated cell feeding and harvesting in a closed system.

The CliniMACS Prodigy Adherent Cell Culture System offers nine modules that automate different workflow steps required for expansion and differentiation of adherent cell types. Flexible combination of these modules, together with full control of the manufacturing parameters, allow for individual, customizable manufacturing workflows to suit a large variety of applications. Cell manufacturing takes place in the fully closed and GMP-compliant CliniMACS Prodigy Tubing Set 730, whilst external culture vessels can be easily connected to bring cell manufacturing to larger scale.

Modules of the CliniMACS Prodigy Adherent Cell Culture System


Preparation of the system for all subsequent cell culture steps

Density gradient

Density gradient centrifugation of primary cell material


Coating of the CliniMACS Prodigy chamber or external culture vessels (ECVs)


Seeding of cells in the CliniMACS Prodigy chamber or ECVs


Cell cultivations in the CliniMACS Prodigy chamber

Media change

Media change in the CliniMACS Prodigy chamber or ECVs


Harvest and formulation of the final cell product


Guided step-by-step deinstallation of the tubing set


Completion of the process

For further information on the CliniMACS Prodigy® Adherent Cell Culture System and its modules click here.

About Miltenyi Biotec:

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy, from basic and translational research to clinical application. With over 3,000 employees in 28 countries Miltenyi Biotec is dedicated advancing biomedical sciences and developing novel therapies for unmet clinical needs.

Media Contact:

Miltenyi Biotec B.V. & Co. KG
James Hafseth

Record changed: 2020-07-24


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Miltenyi Biotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top